Table 2. Treatment trials for WNV.

TREATMENT
Title	NCT Number	Dates	Phase	Status	Interventions	Number Enrolled	Sponsor/ Collaborators	Publications
IVIG—West Nile Encephalitis: Safety and Efficacy	NCT00068055	Posted: 9/8/2003 Completed: 12/2006	1, 2	Completed	Omr-lgG-am vs standard IVIG (Polygam S/D) vs Placebo (normal saline)	62	NIAID*	PMID: 31625835
Omr-IgG-am for Treating Patients With or at High Risk for West Nile Virus Disease	NCT00069316	Posted: 9/23/2003 Completed: 6/27/2007	2	Completed	Omr-lgG-am vs standard IVIG (Polygam S/D) vs Placebo (normal saline)	2	National Institutes of Health Clinical Center	Cited in an observational study of WNV neurologic outcomes (PMID: 24884681), no published reports of use for treatment of WNV identified.
An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease	NCT00091845	Posted: 9/24/2004 Completed: 11/2004	1	Terminated	AVI-4020 Injection (multiple doses)	50 (target enrollment, actual enrollment not reported)	Sarepta Therapeutics, Inc.	No published scientific reports identified.
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020	NCT00387283	Posted: 10/13/2006 Completed: 6/2009	1	Completed	AVI-4020 Injection	14 (target) 11 (actual)	Sarepta Therapeutics, Inc.	Press Release: https://investorrelations.sarepta.com/news-releases/news-release-details/avi-biopharma-announces-positive-clinical-trial-results
A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults	NCT00515385	Posted: 8/13/2007 Completed: 1/2009	1	Completed	MGAWN1 vs Placebo (normal saline)	40	MacroGenics, NIAID*	PMID: 20350945
Treatment of West Nile Virus With MGAWN1	NCT00927953	Posted: 6/25/2009 Completed: 5/2011	2	Terminated	MGAWN1 vs Placebo (normal saline)	13	MacroGenics, NIAID*	No published scientific reports identified.

*NIAID, National Institute of Allergy and Infectious Diseases.

WNV, West Nile virus.